EMA recommends restricting use of Tecovirimat SIGA

View source ↗

Summary

EMA recommends restricting the use of Tecovirimat SIGA because it was not effective for treating mpox in randomized clinical trials.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mpox

Drugs mentioned

• Tecovirimat (tecovirimat)

Snippet

The medicine was not effective for the treatment of mpox in randomised clinical trials